Skip to main content
Top

Breast Cancer Research and Treatment

Issue 2/2011

Content (35 Articles)

Preclinical study

Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73

Su Wei Wong, Kai Hung Tiong, Weng Yip Kong, Yuen Chee Yue, Choon Hooi Chua, Jae Ying Lim, Chai Yuin Lee, Sean I. Quah, Cindy Fow, Cyril Chung, Irene So, Boon Shing Tan, Heng Lungh Choo, Rozita Rosli, Soon-Keng Cheong, Chee-Onn Leong

Preclinical study

RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype

Hany Onsy Habashy, Desmond G. Powe, Enrico Glaab, Graham Ball, Inmaculada Spiteri, Natalio Krasnogor, Jonathan M. Garibaldi, Emad A. Rakha, Andrew R. Green, C. Caldas, Ian O. Ellis

Preclinical study

Accumulation of mutations over the entire mitochondrial genome of breast cancer cells obtained by tissue microdissection

Liane Fendt, Harald Niederstätter, Gabriela Huber, Bettina Zelger, Martina Dünser, Christof Seifarth, Alexander Röck, Georg Schäfer, Helmut Klocker, Walther Parson

Open Access Preclinical study

CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo

Manuel Koch, Fadi Hussein, Andreas Woeste, Carsten Gründker, Karl Frontzek, Günter Emons, Thomas Hawighorst

Preclinical study

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

Teemu T. Junttila, Guangmin Li, Kathryn Parsons, Gail Lewis Phillips, Mark X. Sliwkowski

Preclinical study

Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth

Robert S. Tolhurst, Ross S. Thomas, Fiona J. Kyle, Hetal Patel, Manikandan Periyasamy, Andrew Photiou, Paul T. R. Thiruchelvam, Chun-Fui Lai, Marwa Al-sabbagh, Rosemary A. Fisher, Sayka Barry, Tatjana Crnogorac-Jurcevic, Lesley-Ann Martin, Mitch Dowsett, R. Charles Coombes, Tahereh Kamalati, Simak Ali, Laki Buluwela

Preclinical study

The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy

Gabriel Farante, Stefano Zurrida, Viviana Galimberti, Paolo Veronesi, Giuseppe Curigliano, Alberto Luini, Aron Goldhirsch, Umberto Veronesi

Erratum

Erratum to: The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy

Gabriel Farante, Stefano Zurrida, Viviana Galimberti, Paolo Veronesi, Giuseppe Curigliano, Alberto Luini, Aron Goldhirsch, Umberto Veronesi

Preclinical study

Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts

Mamoru Nukatsuka, Hitoshi Saito, Fumio Nakagawa, Masaaki Abe, Junji Uchida, Jiro Shibata, Ken-ichi Matsuo, Shinzaburo Noguchi, Mamoru Kiniwa

Preclinical study

Distinct function of androgen receptor coactivator ARA70α and ARA70β in mammary gland development, and in breast cancer

Xinyu Wu, Fei Chen, Aysegul Sahin, Constance Albarracin, Zhiheng Pei, Xuanyi Zou, Baljit Singh, Ruliang Xu, Garrett Daniels, Yirong Li, Jianjun Wei, Marvin Blake, Robert J. Schneider, Pamela Cowin, Peng Lee

Clinical Trial

Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial

F. P. O’Malley, S. Chia, D. Tu, L. E. Shepherd, M. N. Levine, D. Huntsman, V. H. Bramwell, I. L. Andrulis, K. I. Pritchard

Clinical trial

Effects of music therapy on pain among female breast cancer patients after radical mastectomy: results from a randomized controlled trial

Xiao-Mei Li, Hong Yan, Kai-Na Zhou, Shao-Nong Dang, Duo-Lao Wang, Yin-Ping Zhang

Clinical trial

Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control

Jeffrey M. Albert, Aman U. Buzdar, Reina Guzman, Pamela K. Allen, Eric A. Strom, George H. Perkins, Wendy A. Woodward, Karen E. Hoffman, Welela Tereffe, Kelly K. Hunt, Thomas A. Buchholz, Julia L. Oh

Clinical trial

Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients

T. Vandorpe, A. Smeets, B. Van Calster, K. Van Hoorde, K. Leunen, F. Amant, Ph. Moerman, K. Deraedt, O. Brouckaert, S. Van Huffel, H. Wildiers, M. R. Christiaens, P. Neven

Clinical trial

Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy

R. I. Lalisang, F. L. G. Erdkamp, C. J. Rodenburg, C. T. A. M. Knibbeler-van Rossum, J. W. R. Nortier, A. van Bochove, P. H. Th. J. Slee, E. E. Voest, J. A. Wils, J. Wals, O. J. L. Loosveld, A. E. M. Smals, G. H. Blijham, V. C. G. Tjan-Heijnen, H. C. Schouten

Clinical trial

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer

E. Razis, M. Bobos, V. Kotoula, A. G. Eleftheraki, H. P. Kalofonos, K. Pavlakis, P. Papakostas, G. Aravantinos, G. Rigakos, I. Efstratiou, K. Petraki, D. Bafaloukos, I. Kostopoulos, D. Pectasides, K. T. Kalogeras, D. Skarlos, G. Fountzilas

Clinical Trial

G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer

Atanas Ignatov, Tanja Ignatov, Christine Weißenborn, Holm Eggemann, Joachim Bischoff, Andrzej Semczuk, Albert Roessner, Serban Dan Costa, Thomas Kalinski

Epidemiology

Current evidence on the relationship between HRAS1 polymorphism and breast cancer risk: a meta-analysis

Chun Zhang, Guo-Qiang Lv, Xian-Ming Yu, Yuan-Long Gu, Jian-Ping Li, Liang-Feng Du, Ping Zhou

Epidemiology

Significant changes in dietary intake and supplement use after breast cancer diagnosis in a UK multicentre study

Louiza S. Velentzis, Mohammed R. Keshtgar, Jayne V. Woodside, Anthony J. Leathem, Ann Titcomb, Katherine Anne Perkins, Monika Mazurowska, Victoria Anderson, Kayleigh Wardell, Marie M. Cantwell

Epidemiology

Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms

Julia Kravchenko, Igor Akushevich, Victoria L. Seewaldt, Amy P. Abernethy, H. Kim Lyerly

Epidemiology

Improved survival of patients with primary distant metastatic breast cancer in the period of 1995–2008. A nationwide population-based study in the Netherlands

J. Ruiterkamp, M. F. Ernst, L. de Munck, M. van der Heiden-van der Loo, E. Bastiaannet, L. V. van de Poll-Franse, K. Bosscha, V. C. G. Tjan-Heijnen, A. C. Voogd

Epidemiology

Image-guided sampling reveals increased stroma and lower glandular complexity in mammographically dense breast tissue

Suling J. Lin, Jennifer Cawson, Prue Hill, Izhak Haviv, Mark Jenkins, John L. Hopper, Melissa C. Southey, Ian G. Campbell, Erik W. Thompson

Epidemiology

Functional polymorphisms in CD166/ALCAM gene associated with increased risk for breast cancer in a Chinese population

Ping Zhou, Liang-Feng Du, Guo-Qiang Lv, Xian-Ming Yu, Yuan-Long Gu, Jian-Ping Li, Chun Zhang

Epidemiology

Breast cancer screening and ethnicity in the United States: implications for health disparities research

Patricia Y. Miranda, Wassim Tarraf, Hector M. González

Epidemiology

Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)

Anne Oberguggenberger, Michael Hubalek, Monika Sztankay, Verena Meraner, Beate Beer, Herbert Oberacher, Johannes Giesinger, Georg Kemmler, Daniel Egle, Eva-Maria Gamper, Barbara Sperner-Unterweger, Bernhard Holzner

Brief Report

Reproductive factors associated with mammographic density: a Korean co-twin control study

Joohon Sung, Yun-Mi Song, Jennifer Stone, Kayoung Lee, Donghun Lee

Brief Report

Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry

B. Graña, L. Fachal, E. Darder, J. Balmaña, T. Ramón y Cajal, I. Blanco, A. Torres, C. Lázaro, O. Diez, C. Alonso, M. Santamariña, A. Velasco, A. Teulé, A. Lasa, A. Blanco, A. Izquierdo, J. Borràs, S. Gutiérrez-Enríquez, A. Vega, J. Brunet

Letter to the Editor

Tumor necrosis factor-α 308 G/A polymorphism in breast cancer risk

Zhishan Ding, Fusheng Jiang, Xinghong Ding, Suhong Chen, Guiyuan Lv

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine